Dr. Zhiyong Ma 马智勇
Chief Physician
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of lung cancer and breast cancer, with a focus on chemotherapy, molecular targeted therapy, and personalized lung cancer care.
Dr. Ma graduated from Henan Medical University in 1983. As Deputy Director of Internal Medicine and Director of the Henan Provincial Lung Cancer Diagnosis and Treatment Center, Dr. Ma specializes in chemotherapy and molecular targeted therapy for solid tumors. Research focuses on multidrug resistance in cancer treatment. Dr. Ma has published nearly 20 papers, co-authored four monographs, and received two scientific achievement awards.
Professional roles
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Executive Committee Member, Clinical Oncology Collaboration Committee (CSCO), China Anti-Cancer Association
- Standing Committee Member, Lung Cancer Professional Committee, Chinese Geriatric Oncology Society
- Vice Chair, Chemotherapy, Lung Cancer, and Bone and Soft Tissue Professional Committees, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Ma Zhiyong). Papers usually list the name as Zhiyong Ma or Ma Z.
Selected publications
64 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Palliat Med, 2021 (senior author): Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor. PubMed 33849094
- Cancer Immunol Immunother, 2020 (senior author): Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. PubMed 31907567
- Cancer Med, 2020 (senior author): Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. PubMed 31769228
- Cancer Gene Ther, 2019 (senior author): Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer. PubMed 30700800
- Lung Cancer, 2019 (senior author): Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. PubMed 30642455
- J Cancer Res Clin Oncol, 2019 (senior author): Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. PubMed 30293117
- Cancer Biol Ther, 2018 (senior author): Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. PubMed 29565727
- Zhongguo Fei Ai Za Zhi, 2018 (senior author): [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer]. PubMed 30037370
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion